Contact us for more information
about our technology and
Tolerogenics is developing novel immunotherapies for allergy & autoimmune diseases based on induction of tolerance. The company is a private-public-partnership with the Luxembourg Institute of Health (LIH).
Tolerogenics S.à.r.l. is offering several investment opportunities in the field of novel allergen- or autoantigen-specific immunotherapies.
Contact us for more information.
29, Rue Henri Koch